{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:27:42Z","timestamp":1794306462266,"version":"4.9.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"9","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072974"],"award-info":[{"award-number":["82072974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572642"],"award-info":[{"award-number":["81572642"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2016YFC1302100"],"award-info":[{"award-number":["2016YFC1302100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai Science and Technology Commission","doi-asserted-by":"crossref","award":["20JC1419200"],"award-info":[{"award-number":["20JC1419200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai Science and Technology Commission","doi-asserted-by":"crossref","award":["16JC1405600"],"award-info":[{"award-number":["16JC1405600"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tissue Microenvironment and Tumor of Chinese Academy of Sciences","award":["202002"],"award-info":[{"award-number":["202002"]}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital Harvard Medical School","doi-asserted-by":"publisher","award":["GIST430\/654"],"award-info":[{"award-number":["GIST430\/654"]}],"id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital Harvard Medical School","doi-asserted-by":"publisher","award":["GIST48"],"award-info":[{"award-number":["GIST48"]}],"id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital Harvard Medical School","doi-asserted-by":"publisher","award":["GIST882"],"award-info":[{"award-number":["GIST882"]}],"id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital Harvard Medical School","doi-asserted-by":"publisher","award":["GIST48B"],"award-info":[{"award-number":["GIST48B"]}],"id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Oncogenic KIT or PDGFRA receptor tyrosine kinase mutations are compelling therapeutic targets in gastrointestinal stromal tumor (GIST), and treatment with the KIT\/PDGFRA inhibitor imatinib is the standard of care for patients with advanced GIST. Polyclonal emergence of KIT\/PDGFRA secondary mutations is the main mechanism of imatinib progression, making it challenging to overcome KIT\/PDGFRA-inhibitor resistance. It is unclear whether there are other therapeutic targets in advanced GIST. Using genome-wide transcriptomic profiling of advanced versus early-stage GIST and CRISPR knockout functional screens, we demonstrate that CDK1 is frequently highly expressed in advanced GIST but not in early-stage GIST across three patient cohorts. High expression of CDK1 was associated with malignancy in GIST. CDK1 was critically required for advanced GIST, including imatinib-resistant GIST. CDK1 ablation led to robust proliferation inhibition. A mass spectrometry-based proteomics screen further revealed that AKT is a novel substrate of CDK1 kinase in GIST. CDK1 bound AKT and regulated its phosphorylation, thereby promoting GIST proliferation and progression. Importantly, a pharmacologic inhibitor of CDK1, RO-3306, disrupted GIST cell proliferation in CDK1 highly expressed GIST but not in CDK1-negative GIST cells and nontransformed fibroblast cells. Treatment with RO-3306 reduced tumor growth in both imatinib-resistant and imatinib-sensitive GIST xenograft mouse models. Our findings suggest that CDK1 represents a druggable therapeutic target in GIST and warrants further testing in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>These findings propose CDK1 as a novel cell-cycle\u2013independent vulnerability in gastrointestinal stromal tumors, representing a new therapeutic opportunity for patients with advanced disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-20-3580","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T11:52:08Z","timestamp":1615895528000},"page":"2481-2494","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors"],"prefix":"10.1158","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-7245","authenticated-orcid":false,"given":"Xiaojing","family":"Lu","sequence":"first","affiliation":[{"name":"1CAS Key Laboratory of Tissue Microenvironment and Tumor, SINH - Changzheng Hospital Joint Center for Translational Medicine, Institutes for Translational Medicine (CAS-SMMU), Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhi","family":"Pang","sequence":"additional","affiliation":[{"name":"1CAS Key Laboratory of Tissue Microenvironment and Tumor, SINH - Changzheng Hospital Joint Center for Translational Medicine, Institutes for Translational Medicine (CAS-SMMU), Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3773-7455","authenticated-orcid":false,"given":"Xiaoxiao","family":"Liu","sequence":"additional","affiliation":[{"name":"1CAS Key Laboratory of Tissue Microenvironment and Tumor, SINH - Changzheng Hospital Joint Center for Translational Medicine, Institutes for Translational Medicine (CAS-SMMU), Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tu","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Shen","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Jia","sequence":"additional","affiliation":[{"name":"1CAS Key Laboratory of Tissue Microenvironment and Tumor, SINH - Changzheng Hospital Joint Center for Translational Medicine, Institutes for Translational Medicine (CAS-SMMU), Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-5934","authenticated-orcid":false,"given":"Jen-Chieh","family":"Lee","sequence":"additional","affiliation":[{"name":"4Department and Graduate Institute of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-5467","authenticated-orcid":false,"given":"Yuexiang","family":"Wang","sequence":"additional","affiliation":[{"name":"1CAS Key Laboratory of Tissue Microenvironment and Tumor, SINH - Changzheng Hospital Joint Center for Translational Medicine, Institutes for Translational Medicine (CAS-SMMU), Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"2022061706390503600_bib1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc3143","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Corless","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2022061706390503600_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-2-14","article-title":"The epidemiology of sarcoma","volume":"2","author":"Burningham","year":"2012","journal-title":"Clin Sarcoma Res"},{"key":"2022061706390503600_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"2022061706390503600_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"key":"2022061706390503600_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"2022061706390503600_bib6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"2022061706390503600_bib7","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022061706390503600_bib8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/2159-8290.CD-NB2020-003","article-title":"Avapritinib approved for GIST subgroup","volume":"10","author":"Dolgin","year":"2020","journal-title":"Cancer Discov"},{"key":"2022061706390503600_bib9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CCO.0000000000000549","article-title":"New therapeutic agents in gastrointestinal stromal tumours","volume":"31","author":"Falkenhorst","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"2022061706390503600_bib10","first-page":"334","article-title":"Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain","volume":"10","author":"Grunewald","year":"2020","journal-title":"Cancer Discov"},{"key":"2022061706390503600_bib11","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1158\/1078-0432.CCR-09-0190","article-title":"Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors","volume":"15","author":"Gramza","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061706390503600_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","article-title":"Heterogeneity of kinase inhibitor resistance mechanisms in GIST","volume":"216","author":"Liegl","year":"2008","journal-title":"J Pathol"},{"key":"2022061706390503600_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/01.pas.0000213307.05811.f0","article-title":"Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-kit mutations","volume":"31","author":"Agaimy","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"2022061706390503600_bib14","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.humpath.2013.07.020","article-title":"Small gastrointestinal stromal tumor in the stomach: identification of precursor for clinical gastrointestinal stromal tumor using c-kit and alpha-smooth muscle actin expression","volume":"44","author":"Mikami","year":"2013","journal-title":"Hum Pathol"},{"key":"2022061706390503600_bib15","first-page":"3899","article-title":"DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance","volume":"60","author":"El-Rifai","year":"2000","journal-title":"Cancer Res"},{"key":"2022061706390503600_bib16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ng.2974","article-title":"Dystrophin is a tumor suppressor in human cancers with myogenic programs","volume":"46","author":"Wang","year":"2014","journal-title":"Nat Genet"},{"key":"2022061706390503600_bib17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.cell.2007.03.052","article-title":"Integrative genomic approaches identify IKBKE as a breast cancer oncogene","volume":"129","author":"Boehm","year":"2007","journal-title":"Cell"},{"key":"2022061706390503600_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"2022061706390503600_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cell.2015.06.059","article-title":"A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks","volume":"162","author":"Parnas","year":"2015","journal-title":"Cell"},{"key":"2022061706390503600_bib20","doi-asserted-by":"crossref","first-page":"e0149099","DOI":"10.1371\/journal.pone.0149099","article-title":"CDK1 is a synthetic lethal target for KRAS mutant tumours","volume":"11","author":"Costa-Cabral","year":"2016","journal-title":"PLoS One"},{"key":"2022061706390503600_bib21","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.0600447103","article-title":"Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1","volume":"103","author":"Vassilev","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706390503600_bib22","doi-asserted-by":"crossref","first-page":"22746","DOI":"10.1073\/pnas.1914542116","article-title":"Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors","volume":"116","author":"Pang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706390503600_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.6004\/jnccn.2016.0078","article-title":"Soft tissue sarcoma, version 2.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"von Mehren","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"2022061706390503600_bib24","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1158\/0008-5472.CAN-06-0165","article-title":"Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor","volume":"66","author":"Bauer","year":"2006","journal-title":"Cancer Res"},{"key":"2022061706390503600_bib25","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nprot.2017.016","article-title":"Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening","volume":"12","author":"Joung","year":"2017","journal-title":"Nat Protoc"},{"key":"2022061706390503600_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022061706390503600_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022061706390503600_bib28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nature02062","article-title":"Targets of the cyclin-dependent kinase Cdk1","volume":"425","author":"Ubersax","year":"2003","journal-title":"Nature"},{"key":"2022061706390503600_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2022061706390503600_bib30","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1074\/mcp.M116.059394","article-title":"Identification of candidate cyclin-dependent kinase 1 (cdk1) substrates in mitosis by quantitative phosphoproteomics","volume":"15","author":"Petrone","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"2022061706390503600_bib31","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jmb.2019.04.005","article-title":"Allosteric regulation of cyclin-B binding by the charge state of catalytic lysine in CDK1 is essential for cell-cycle progression","volume":"431","author":"Deota","year":"2019","journal-title":"J Mol Biol"},{"key":"2022061706390503600_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cdd.2016.84","article-title":"CDK1-PDK1-PI3K\/Akt signaling pathway regulates embryonic and induced pluripotency","volume":"24","author":"Wang","year":"2017","journal-title":"Cell Death Differ"},{"key":"2022061706390503600_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2022061706390503600_bib34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"},{"key":"2022061706390503600_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0027-5107(01)00111-7","article-title":"Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death","volume":"477","author":"Herceg","year":"2001","journal-title":"Mutat Res"},{"key":"2022061706390503600_bib36","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1158\/1078-0432.CCR-14-1823","article-title":"Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy","volume":"20","author":"Van Looy","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022061706390503600_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/1078-0432.CCR-16-0529","article-title":"Combination of imatinib mesylate and AKT inhibitor provides synergistic effects in preclinical study of gastrointestinal stromal tumor","volume":"23","author":"Zook","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061706390503600_bib38","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1517\/14656566.2014.937707","article-title":"Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors","volume":"15","author":"Nishida","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2022061706390503600_bib39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"2022061706390503600_bib40","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"2022061706390503600_bib41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.molcel.2020.03.010","article-title":"CDK1 controls global epigenetic landscape in embryonic stem cells","volume":"78","author":"Michowski","year":"2020","journal-title":"Mol Cell"},{"key":"2022061706390503600_bib42","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022061706390503600_bib43","doi-asserted-by":"crossref","first-page":"103029","DOI":"10.1016\/j.critrevonc.2020.103029","article-title":"Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: a comprehensive review","volume":"153","author":"Assi","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2022061706390503600_bib44","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706390503600_bib45","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","author":"Patnaik","year":"2016","journal-title":"Cancer Discov"},{"key":"2022061706390503600_bib46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-017-4385-3","article-title":"Cyclin-dependent kinase 4\/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib","volume":"166","author":"Kwapisz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2022061706390503600_bib47","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nm1606","article-title":"Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC","volume":"13","author":"Goga","year":"2007","journal-title":"Nat Med"},{"key":"2022061706390503600_bib48","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm.2377","article-title":"Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nat Med"},{"key":"2022061706390503600_bib49","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-19-1069","article-title":"Preclinical activity of PI3K inhibitor copanlisib in gastrointestinal stromal tumor","volume":"19","author":"Garcia-Valverde","year":"2020","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/9\/2481\/3094370\/2481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/9\/2481\/3094370\/2481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T16:38:50Z","timestamp":1655483930000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/9\/2481\/670606\/Integrated-Screens-Identify-CDK1-as-a-Therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,3,16]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-20-3580","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6513673","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6513673.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22430641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22430641.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22430644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22430644.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]}}}